A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma in vivo
Author:
Publisher
Elsevier BV
Subject
Multidisciplinary
Reference42 articles.
1. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nat. Rev. Gastroenterol. Hepatol.,2020
2. An intelligent NIR-responsive chelate copper-based anticancer nanoplatform for synergistic tumor targeted chemo-phototherapy;Feng;Nanoscale,2017
3. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment;Sapisochin;Hepatology,2016
4. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma;Jarnagin;Ann. Surg.,2001
5. Cholangiocarcinoma - evolving concepts and therapeutic strategies;Rizvi;Nat. Rev. Clin. Oncol.,2018
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Focusing on the Immune Cells: Recent Advances in Immunotherapy for Biliary Tract Cancer;Cancer Management and Research;2024-07
2. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-06
3. Bortezomib in Combination with Physachenolide C Reduces the Tumorigenic Properties of KRASmut/P53mut Lung Cancer Cells by Inhibiting c-FLIP;Cancers;2024-02-04
4. Emerging roles of 3D-culture systems in tackling tumor drug resistance;Cancer Drug Resistance;2023-11-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3